Piper Sandler lowered the firm’s price target on Privia Health (PRVA) to $35 from $36 and keeps an Overweight rating on the shares. The firm would be a buyer of Privia’s Q2 beat and raise. Piper’s price target equates to 30-times conservative PSC 2026 adjusted EBITDA for the cleanest model in healthcare delivery with the power to grow earnings at a 20%-plus CAGR over the long-term.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health Group: Strong Performance and Promising Outlook Justify Buy Rating
- Privia Health Reports Strong Q2 2025 Financial Results
- Privia Health Group: Strong Buy Rating Backed by Robust Financial Performance and Strategic Expansion
- Privia Health reports Q2 non-GAAP EPS 24c, consensus 20c
- Privia Health now sees FY25 revenue above previous view $1.08B-$1.09B